Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Plain-language summary
This trial is testing GW5282 combined with golidocitinib for patients with various types of peripheral T-cell lymphoma (PTCL) at various stages of their disease. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
GW5282 combined with Golidocitinib (DRUG): GW5282 and Golidocitinib will be administered in combination as twice daily (BID) and once daily (QD), respectively. The starting dose will be GW5282 40 mg BID combined with golidocitinib 150 mg QD. If tolerated, the dose of GW5282 will be subsequently escalated. | GW5282 combined with Golidocitinib (DRUG): GW5282 and Golidocitinib will be administered at the doses determined during escalation part. | Conventional CHOP regimen (DRUG): CHOP regimen includes the administrations of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
GW5282 combined with Golidocitinib, GW5282 combined with Golidocitinib, Conventional CHOP regimen
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details